Pharmaceutical Cartridges Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Pharmaceutical Cartridges Market is projected to expand from a valuation of USD 2.90 billion in 2025 to USD 4.55 billion by 2031, reflecting a compound annual growth rate of 7.81%. These specialized cylindrical vessels, manufactured from borosilicate glass or polymers, are critical components in drug delivery mechanisms like pen injectors and autoinjectors, ensuring exact dosage accuracy. The market is primarily propelled by the rising prevalence of chronic diseases requiring long-term treatment and a growing preference for patient-centric self-administration. Furthermore, the burgeoning biologics sector reinforces this demand, as it requires high-stability packaging to preserve drug safety and integrity throughout storage and use.

Highlighting the scale of demand, the International Diabetes Federation reported that approximately 589 million adults were living with diabetes globally in 2024, emphasizing the critical need for dependable insulin delivery systems such as cartridge-based pens. Despite these strong growth indicators, market expansion faces potential hurdles due to the significant capital expenditure and technical intricacies involved in manufacturing. The rigorous regulatory requirements for sterility and dimensional precision demand sophisticated production environments, creating barriers that restrict rapid capacity scaling for new market entrants.

Market Drivers

The surging global incidence of chronic conditions, specifically obesity and diabetes, serves as the central catalyst for the uptake of pharmaceutical cartridges. As the number of patients requiring long-term injectable therapies rises, there is an increased dependency on multidose pen injectors that utilize these polymer or glass reservoirs for precise self-administration. This trend is clearly illustrated by the high demand for glucagon-like peptide-1 (GLP-1) receptor agonists, which has required massive manufacturing adjustments to maintain supply. For example, Novo Nordisk’s 2023 Annual Report noted that sales in its Diabetes and Obesity care division rose by 38% to DKK 215.1 billion, demonstrating the widespread adoption of these cartridge-based treatments.

Concurrently, the market is evolving due to the rapid growth of the biologics sector, which necessitates premium packaging solutions. Because biologics and biosimilars frequently feature complex molecular structures sensitive to container surfaces, specialized borosilicate glass or polymers are essential for maintaining stability. This shift is reflected in the financials of major component manufacturers; Schott Pharma’s February 2024 media release regarding Q1 results indicated that revenue from high-value solutions, including advanced containment systems, rose to 53%. To sustain this growth and the wider injectable ecosystem, major pharmaceutical companies are investing heavily in infrastructure, such as Eli Lilly’s 2024 commitment of an additional $5.3 billion to its Lebanon, Indiana facility to enhance active pharmaceutical ingredient production for injectables.

Market Challenges

The expansion of the pharmaceutical cartridge market is substantially constrained by the significant capital expenditure and technical complexity required for manufacturing. Developing these primary packaging components demands specialized facilities capable of meeting stringent regulatory standards for dimensional precision and sterility. These exacting requirements force manufacturers to make large upfront investments in cleanroom environments and advanced machinery, creating significant barriers to entry for new competitors while simultaneously restricting the ability of established players to quickly ramp up production. As a result, the industry struggles to align supply capabilities with the escalating demand for injectable therapies.

The consequences of these manufacturing obstacles are clearly visible in the frequent supply chain disruptions affecting the sterile injectables market. In 2024, the American Society of Health-System Pharmacists reported a record high of 323 active drug shortages, a crisis largely stemming from regulatory delays and manufacturing quality control challenges. This statistic highlights how the rigorous operational demands and compliance burdens involved in producing high-quality delivery systems directly hinder market liquidity and the stability of growth within the sector.

Market Trends

The market is undergoing a transformation with the introduction of large-volume cartridges tailored for wearable injectors, facilitating a transition from intravenous infusions to subcutaneous self-administration for complex biologics. Because high-viscosity formulations for autoimmune diseases and oncology often require doses surpassing the standard 3mL limit of pen injectors, manufacturers are creating 5mL to 10mL cartridges compatible with on-body delivery devices. This innovation reduces reliance on healthcare facilities by enabling home management of chronic conditions. As noted in Schott Pharma’s 2024 Annual Report, the revenue share of high-value solutions - including these large-volume cartridges - rose to 55% of total sales following a 22% year-on-year increase, signaling their vital importance in modern delivery.

At the same time, the industry is widely adopting Ready-to-Use (RTU) sterile cartridge formats, which significantly streamline the fill-finish process for pharmaceutical developers. By outsourcing sterilization, washing, and siliconization to the packaging supplier, drug manufacturers can bypass capital-intensive front-end processing lines and gain operational flexibility for small-batch therapies. This trend is accelerating as major suppliers standardize RTU platforms for filling line compatibility. For instance, Stevanato Group’s Third Quarter 2025 Financial Results reported a 47% year-over-year surge in revenue from high-value solutions, including the EZ-fill RTU portfolio, reaching €147.9 million and highlighting the rapid adoption of pre-sterilized containment systems.

Key Players Profiled in the Pharmaceutical Cartridges Market

• Schott AG
• Gerresheimer AG
• West Pharmaceutical Services, Inc.
• Stevanato Group
• Nipro Corporation
• Berry Global Group, Inc.
• SGD Pharma
• Baxter International Inc.
• Vetter Pharma International GmbH
• Catalent, Inc.

Report Scope

In this report, the Global Pharmaceutical Cartridges Market has been segmented into the following categories:

Pharmaceutical Cartridges Market, by Material Type:

• Glass Cartridges
• Plastic Cartridges
• Rubber

Pharmaceutical Cartridges Market, by Application:

• Dental Anesthesia
• Pen Injectors
• Autoinjectors
• Wearable Injectors

Pharmaceutical Cartridges Market, by Chamber Type:

• Dual Chamber
• Large Volume

Pharmaceutical Cartridges Market, by Size:

• 0.5ml
• 1.8ml
• 2ml to 2.5ml
• 3ml
• 5ml
• More than 10ml

Pharmaceutical Cartridges Market, by Therapeutics Area:

• Ophthalmology
• Respiratory
• Neurology
• Oncology
• Immunology
• Cardiology
• Diabetes
• Dental
• Others

Pharmaceutical Cartridges Market, by End User:

• Pharmaceuticals
• Biotechnology
• Research Organizations
• Others

Pharmaceutical Cartridges Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Cartridges Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.